13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab

✍ Scribed by W.J. Sandborn; S. Vermeire; G. D'Haens; J.F. Colombel; R.N. Fedorak; M.E. Spehlmann; M.T. Abreu; K. Mitchev; C. Jamoul; P. Rutgeerts

• Book ID: 119636119
• Publisher: Oxford University Press
• Year: 2009
• Tongue: English
• Weight: 62 KB
• Volume: 3
• Category: Article
• ISSN: 1873-9946
• DOI: 10.1016/s1873-9946(09)60025-8